logo-loader
viewQ BioMed Inc.

Q BioMed discovers two key biomarkers in study of pediatric nonverbal autism

Q BioMed Inc (OTCMKTS:QBIO) CEO Denis Corin tells Proactive Investors the New York-based biotech has made a "tremendous" discovery in the first two biomarkers for pediatric nonverbal autism.

Corin says this allows the company a greater chance of success in its clinical study for drug candidate QBM-001, as these new biomarkers clearly define the patient population.

Quick facts: Q BioMed Inc.

Price: 1.81 USD

OTCQB:QBIO
Market: OTCQB
Market Cap: $41.1 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Q BioMed advancing its liver cancer treatment through the pipeline

Q BioMed Inc (OTCMKTS:QBIO) CEO Denis Corin tells Proactive the biotech will advance Uttroside-B in its portfolio and move it quickly towards monetization. Corin says the efficacy of Uttroside-B, a potent saponin, was demonstrated in a preclinical study published in the November 2016 issue of...

1 week, 4 days ago

2 min read